Form 8-K - Current report:
SEC Accession No. 0001564590-19-040690
Filing Date
2019-11-06
Accepted
2019-11-06 08:30:22
Documents
3
Period of Report
2019-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agle-8k_20191106.htm 8-K 37774
2 EX-99.1 agle-ex991_6.htm EX-99.1 259700
3 GRAPHIC g5q2olk05zxs000001.jpg GRAPHIC 3061
  Complete submission text file 0001564590-19-040690.txt   303041
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 191195162
SIC: 2834 Pharmaceutical Preparations